Inhibitor-Sensitive FGFR 2 and FGFR 3 Mutations in Lung Squamous Cell Carcinoma

A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung SCC) has recently been reported, enabling the identification of genomic events that contribute to the oncogenesis of this disease. In lung SCC, one of the most frequently altered receptor tyrosine kinase families is the fibroblast growth factor receptor (FGFR) family, with amplification or mutation observed in all four family members. Here, we describe the oncogenic nature of mutations observed in FGFR2 and FGFR3, each of which are observed in 3% of samples, for a mutation rate of 6% across both genes. Using cell culture and xenograft models, we show that several of these mutations drive cellular transformation. Transformation can be reversed by small-molecule FGFR inhibitors currently being developed for clinical use. We also show that mutations in the extracellular domains of FGFR2 lead to constitutive FGFR dimerization. In addition, we report a patient with an FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib. These findings provide new insights into driving oncogenic events in a subset of lung squamous cancers, and recommend future clinical studies with FGFR inhibitors in patients with lung and head and neck SCC. Cancer Res; 73(16); 5195–205. 2013 AACR.

[1]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[2]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[3]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[4]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[5]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[6]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[7]  Andrew P Thomas,et al.  AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. , 2012, Cancer research.

[8]  T. Clackson,et al.  Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models , 2012, Molecular Cancer Therapeutics.

[9]  Pascal Furet,et al.  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.

[10]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[11]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[12]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[13]  P. Pollock,et al.  Targeting mutant fibroblast growth factor receptors in cancer. , 2011, Trends in molecular medicine.

[14]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[15]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[16]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[17]  Christopher R. Cabanski,et al.  Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types , 2010, Clinical Cancer Research.

[18]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[19]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[20]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[21]  T. Fennell,et al.  Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts , 2009, Genome Biology.

[22]  Johanna M Jansen,et al.  Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. , 2009, Journal of medicinal chemistry.

[23]  P. Meltzer,et al.  Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma , 2009, Molecular Cancer Research.

[24]  Kristian Cibulskis,et al.  Drug-sensitive FGFR2 mutations in endometrial carcinoma , 2008, Proceedings of the National Academy of Sciences.

[25]  J. Fargnoli,et al.  Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) , 2008, Journal of medicinal chemistry.

[26]  Yuji Yamamoto,et al.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.

[27]  P. Pollock,et al.  Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes , 2007, Oncogene.

[28]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[29]  G. Sonpavde,et al.  Pazopanib: A novel multitargeted tyrosine kinase inhibitor , 2007, Current oncology reports.

[30]  Des Powe,et al.  FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.

[31]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[32]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[33]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[34]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[35]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[36]  P. Marie,et al.  FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. , 2002, Genes & development.

[37]  M. Ittmann,et al.  Alternative splicing of fibroblast growth factor receptors in human prostate cancer , 2001, The Prostate.

[38]  G. Waksman,et al.  Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Joseph Schlessinger,et al.  Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity , 2000, Cell.

[40]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[41]  A. N. Meyer,et al.  Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[42]  W. Mckeehan,et al.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy , 1993, Molecular and cellular biology.